The market for gene/cell therapy is low because there is not that many FDA approved products in this field. In fact, if MSB gets approval, we will be the first in allogenic MSC therapy with FDA approval. The current market does not reflect the future market in this field of medicine once we get the FDA approval, especially for cell-based therapy for back pain, heart failure, and IBD indications.
The market for gene/cell therapy is low because there is not...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.16 |
Change
0.070(6.45%) |
Mkt cap ! $1.318B | |||
| Open | High | Low | Value | Volume |
| $1.12 | $1.20 | $1.11 | $20.88M | 17.94M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 59978 | $1.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.16 | 34019 | 3 |
View Market Depth
| Last trade - 16.10pm 06/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.15 |
Change
0.070 ( 5.63 %) |
||||
| Open | High | Low | Volume | ||
| $1.12 | $1.20 | $1.12 | 3733217 | ||
| Last updated 15.59pm 06/05/2024 ? | |||||
| MSB (ASX) Chart |